{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:40:28Z","timestamp":1792093228600,"version":"4.4.0"},"reference-count":181,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001509","name":"Royal Society Te Ap\u0101rangi","doi-asserted-by":"publisher","award":["RDF-UOO1802"],"award-info":[{"award-number":["RDF-UOO1802"]}],"id":[{"id":"10.13039\/501100001509","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001509","name":"Royal Society Te Ap\u0101rangi","doi-asserted-by":"publisher","award":["20-UOO-004"],"award-info":[{"award-number":["20-UOO-004"]}],"id":[{"id":"10.13039\/501100001509","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cancer is one of the leading causes of death worldwide. Conventional therapies, including surgery, radiation, and chemotherapy have achieved increased survival rates for many types of cancer over the past decades. However, cancer recurrence and\/or metastasis to distant organs remain major challenges, resulting in a large, unmet clinical need. Oligonucleotide therapeutics, which include antisense oligonucleotides, small interfering RNAs, and aptamers, show promising clinical outcomes for disease indications such as Duchenne muscular dystrophy, familial amyloid neuropathies, and macular degeneration. While no approved oligonucleotide drug currently exists for any type of cancer, results obtained in preclinical studies and clinical trials are encouraging. Here, we provide an overview of recent developments in the field of oligonucleotide therapeutics in oncology, review current clinical trials, and discuss associated challenges.<\/jats:p>","DOI":"10.3390\/ijms22073295","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T15:42:19Z","timestamp":1616600539000},"page":"3295","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":173,"title":["Recent Advances in Oligonucleotide Therapeutics in Oncology"],"prefix":"10.3390","volume":"22","author":[{"given":"Haoyu","family":"Xiong","sequence":"first","affiliation":[{"name":"Department of Biochemistry, University of Otago, Dunedin 9016, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh N.","family":"Veedu","sequence":"additional","affiliation":[{"name":"Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth 6150, Australia"},{"name":"Perron Institute for Neurological and Translational Science, Perth 6009, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6120-2744","authenticated-orcid":false,"given":"Sarah D.","family":"Diermeier","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, University of Otago, Dunedin 9016, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"Stewart, B.W., and Wild, C.P. (2014). World Cancer Report 2014, International Agency for Research on Cancer."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S300","DOI":"10.37765\/ajmc.2020.88534","article-title":"Screening for cancer: The economic, medical, and psychosocial issues","volume":"26","author":"Brill","year":"2020","journal-title":"Am. J. Manag. Care"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00109-016-1393-4","article-title":"Adapting conventional cancer treatment for immunotherapy","volume":"94","author":"Qiao","year":"2016","journal-title":"J. Mol. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40880-017-0206-7","article-title":"Cancer metastasis: Issues and challenges","volume":"36","author":"Qian","year":"2017","journal-title":"Chin. J. Cancer"},{"key":"ref_6","unstructured":"Editore, S. (2014). Management of Adverse Effects of Radiotherapy, SICS Editore."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3892\/ijo.2018.4661","article-title":"From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review)","volume":"54","author":"Schirrmacher","year":"2019","journal-title":"Int. J. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100738","DOI":"10.1016\/j.tranon.2019.12.010","article-title":"Resistance to Checkpoint Inhibition in Cancer Immunotherapy","volume":"13","author":"Barrueto","year":"2020","journal-title":"Transl. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1084\/jem.20161462","article-title":"What does PD-L1 positive or negative mean?","volume":"213","author":"Ribas","year":"2016","journal-title":"J. Exp. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Stoiber, S., Cadilha, B.L., Benmebarek, M.-R., Lesch, S., Endres, S., and Kobold, S. (2019). Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy. Cells, 8.","DOI":"10.3390\/cells8050472"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1155\/2019\/3425291","article-title":"Efficiency of CAR-T Therapy for Treatment of Solid Tumor in Clinical Trials: A Meta-Analysis","volume":"2019","author":"Hou","year":"2019","journal-title":"Dis. Markers"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13046-019-1094-2","article-title":"Clinical development of targeted and immune based anti-cancer therapies","volume":"38","author":"Seebacher","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","article-title":"Comprehensive review of targeted therapy for colorectal cancer","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails","volume":"19","author":"Lacouture","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.cbi.2019.05.028","article-title":"Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases","volume":"308","author":"Mehta","year":"2019","journal-title":"Chem. Biol. Interact."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1038\/mtna.2014.32","article-title":"Oligonucleotide aptamers: New tools for targeted cancer therapy","volume":"3","author":"Sun","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.biotechadv.2018.11.001","article-title":"Three decades of nucleic acid aptamer technologies: Lessons learned, progress and opportunities on aptamer development","volume":"37","author":"Wang","year":"2019","journal-title":"Biotechnol. Adv."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1080\/15476286.2016.1236173","article-title":"In vitro evolution of chemically-modified nucleic acid aptamers: Pros and cons, and comprehensive selection strategies","volume":"13","author":"Lipi","year":"2016","journal-title":"RNA Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/nat.2020.0845","article-title":"The 10th Oligonucleotide Therapy Approved: Golodirsen for Duchenne Muscular Dystrophy","volume":"30","author":"Corey","year":"2020","journal-title":"Nucleic Acid Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2013.05.001","article-title":"Defibrotide: Properties and clinical use of an old\/new drug","volume":"59","author":"Pescador","year":"2013","journal-title":"Vascul. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/978-3-642-31659-3_9","article-title":"Oligonucleotide therapeutics in cancer","volume":"158","author":"Wan","year":"2013","journal-title":"Cancer Treat. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.addr.2015.04.005","article-title":"Cellular uptake and intracellular trafficking of oligonucleotides","volume":"87","author":"Juliano","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1093\/nar\/gkw236","article-title":"The delivery of therapeutic oligonucleotides","volume":"44","author":"Juliano","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e1594","DOI":"10.1002\/wrna.1594","article-title":"The powerful world of antisense oligonucleotides: From bench to bedside","volume":"11","author":"Quemener","year":"2020","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.chembiol.2012.07.011","article-title":"Designing chemically modified oligonucleotides for targeted gene silencing","volume":"19","author":"Deleavey","year":"2012","journal-title":"Chem. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Dhuri, K., Bechtold, C., Quijano, E., Pham, H., Gupta, A., Vikram, A., and Bahal, R. (2020). Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development. J. Clin. Med. Res., 9.","DOI":"10.3390\/jcm9062004"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Thurston, D.E. (2006). Chemistry and Pharmacology of Anticancer Drugs, CRC Press.","DOI":"10.1201\/9781420008906"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Younis, H.S., Templin, M., Whiteley, L.O., Kornbrust, D., Kim, T.W., and Henry, S.P. (2017). Overview of the Nonclinical Development Strategies and Class-Effects of Oligonucleotide-Based Therapeutics. A Comprehensive Guide to Toxicology in Nonclinical Drug Development, Academic Press.","DOI":"10.1016\/B978-0-12-803620-4.00028-1"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1093\/nar\/gkaa299","article-title":"Phosphorothioate modified oligonucleotide-protein interactions","volume":"48","author":"Crooke","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.omtn.2018.11.007","article-title":"Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics","volume":"14","author":"Le","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/nar\/gky1260","article-title":"Characterization of the interactions of chemically-modified therapeutic nucleic acids with plasma proteins using a fluorescence polarization assay","volume":"47","author":"Gaus","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/0192623314551840","article-title":"Antisense oligonucleotide therapies: The promise and the challenges from a toxicologic pathologist\u2019s perspective","volume":"43","author":"Frazier","year":"2015","journal-title":"Toxicol. Pathol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/ard.1995.5.241","article-title":"Phosphorothioate oligodeoxynucleotides: Antisense or anti-protein?","volume":"5","author":"Krieg","year":"1995","journal-title":"Antisense Res. Dev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nbt.3779","article-title":"Cellular uptake and trafficking of antisense oligonucleotides","volume":"35","author":"Crooke","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"ref_36","first-page":"93","article-title":"Antisense Oligonucleotides: Treatment Strategies and Cellular Internalization","volume":"3","author":"Miller","year":"2016","journal-title":"RNA Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/83489","article-title":"Phosphoramidate oligonucleotides as potent antisense molecules in cells and in vivo","volume":"19","author":"Faria","year":"2001","journal-title":"Nat. Biotechnol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"7661","DOI":"10.1016\/S0040-4039(99)01584-1","article-title":"Oligonucleotide N3\u2032\u2192P5\u2032 thiophosphoramidates: Synthesis and properties","volume":"40","author":"Krisztina","year":"1999","journal-title":"Tetrahedron Lett."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Nair, P.R. (2019). Delivering Combination Chemotherapies and Targeting Oncogenic Pathways via Polymeric Drug Delivery Systems. Polymers, 11.","DOI":"10.3390\/polym11040630"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1046\/j.1432-1033.2003.03555.x","article-title":"Antisense technologies. Improvement through novel chemical modifications","volume":"270","author":"Kurreck","year":"2003","journal-title":"Eur. J. Biochem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.4161\/cc.7.16.6461","article-title":"Insights into RNA\/DNA hybrid recognition and processing by RNase H from the crystal structure of a non-specific enzyme-dsDNA complex","volume":"7","author":"Pallan","year":"2008","journal-title":"Cell Cycle"},{"key":"ref_42","unstructured":"Vitravene Study Group (2002). A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am. J. Ophthalmol., 133, 467\u2013474."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1021\/jm701537z","article-title":"Comparing in vitro and in vivo activity of 2\u2032-O-[2-(methylamino)-2-oxoethyl]- and 2\u2032-O-methoxyethyl-modified antisense oligonucleotides","volume":"51","author":"Prakash","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1093\/nar\/gkaa126","article-title":"Comparison of the efficacy of MOE and PMO modifications of systemic antisense oligonucleotides in a severe SMA mouse model","volume":"48","author":"Sheng","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.ymthe.2017.06.002","article-title":"RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus","volume":"25","author":"Liang","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1074-5521(00)00058-2","article-title":"Locked nucleic acid (LNA): Fine-tuning the recognition of DNA and RNA","volume":"8","author":"Braasch","year":"2001","journal-title":"Chem. Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1093\/nar\/gkl756","article-title":"Position-dependent effects of locked nucleic acid (LNA) on DNA sequencing and PCR primers","volume":"34","author":"Levin","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nbt.3948","article-title":"Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides","volume":"35","author":"Iwamoto","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Sardone, V., Zhou, H., Muntoni, F., Ferlini, A., and Falzarano, M.S. (2017). Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease. Molecules, 22.","DOI":"10.3390\/molecules22040563"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10059-009-0134-8","article-title":"A highly effective and long-lasting inhibition of miRNAs with PNA-based antisense oligonucleotides","volume":"28","author":"Oh","year":"2009","journal-title":"Mol. Cells"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.ymthe.2020.06.015","article-title":"Delivery of oligonucleotides to the liver with GalNAc: From research to registered therapeutic drug","volume":"28","author":"Debacker","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s41061-020-0286-8","article-title":"Oligonucleotide-polymer conjugates: From molecular basics to practical application","volume":"378","author":"Xiao","year":"2020","journal-title":"Top. Curr. Chem. J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.3389\/fimmu.2019.02388","article-title":"The Role of TLRs in Anti-cancer Immunity and Tumor Rejection","volume":"10","author":"Khan","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ebiom.2019.07.005","article-title":"TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes","volume":"45","author":"Schleimann","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s40425-019-0738-2","article-title":"TLR9 acts as a sensor for tumor-released DNA to modulate anti-tumor immunity after chemotherapy","volume":"7","author":"Kang","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.addr.2008.12.008","article-title":"Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists","volume":"61","author":"Vollmer","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Hager, S., Fittler, F.J., Wagner, E., and Bros, M. (2020). Nucleic Acid-Based Approaches for Tumor Therapy. Cells, 9.","DOI":"10.3390\/cells9092061"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1002\/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U","article-title":"Identification of CpG oligonucleotide sequences with high induction of IFN-alpha\/beta in plasmacytoid dendritic cells","volume":"31","author":"Krug","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/374546a0","article-title":"CpG motifs in bacterial DNA trigger direct B-cell activation","volume":"374","author":"Krieg","year":"1995","journal-title":"Nature"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fnagi.2020.00036","article-title":"Class C CpG Oligodeoxynucleotide Immunomodulatory Response in Aged Squirrel Monkey","volume":"12","author":"Nehete","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"6377","DOI":"10.1016\/j.vaccine.2014.06.065","article-title":"Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer","volume":"32","author":"Scheiermann","year":"2014","journal-title":"Vaccine"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2174\/138920210793175895","article-title":"MicroRNA: Biogenesis, Function and Role in Cancer","volume":"11","author":"Macfarlane","year":"2010","journal-title":"Curr. Genom."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrm3838","article-title":"Regulation of microRNA biogenesis","volume":"15","author":"Ha","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.1016\/j.febslet.2005.08.079","article-title":"Dicing and slicing: The core machinery of the RNA interference pathway","volume":"579","author":"Hammond","year":"2005","journal-title":"FEBS Lett."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"15004","DOI":"10.1038\/sigtrans.2015.4","article-title":"The role of MicroRNAs in human cancer","volume":"1","author":"Peng","year":"2016","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/ijc.23343","article-title":"MicroRNAs and cancer: Profile, profile, profile","volume":"122","author":"Barbarotto","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/cgt.2010.18","article-title":"MicroRNA and drug resistance","volume":"17","author":"Ma","year":"2010","journal-title":"Cancer Gene Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","article-title":"MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases","volume":"16","author":"Rupaimoole","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/35053110","article-title":"Role for a bidentate ribonuclease in the initiation step of RNA interference","volume":"409","author":"Bernstein","year":"2001","journal-title":"Nature"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.2147\/IJN.S200253","article-title":"Small interfering RNAs (siRNAs) in cancer therapy: A nano-based approach","volume":"14","author":"Mahmoodi","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3389\/fphar.2019.00444","article-title":"Current development of siRNA bioconjugates: From research to the clinic","volume":"10","author":"Chernikov","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Tatiparti, K., Sau, S., Kashaw, S.K., and Iyer, A.K. (2017). SiRNA delivery strategies: A comprehensive review of recent developments. Nanomaterials, 7.","DOI":"10.3390\/nano7040077"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Fu, Z., and Xiang, J. (2020). Aptamers, the Nucleic Acid Antibodies, in Cancer Therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21082793"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Pastor, F. (2016). Aptamers: A New Technological Platform in Cancer Immunotherapy. Pharmaceuticals, 9.","DOI":"10.3390\/ph9040064"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"6902","DOI":"10.7150\/jca.49532","article-title":"Application and development of aptamer in cancer: From clinical diagnosis to cancer therapy","volume":"11","author":"Han","year":"2020","journal-title":"J. Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1089\/nat.2017.0680","article-title":"Effect of chemical modifications on aptamer stability in serum","volume":"27","author":"Kratschmer","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Ni, S., Yao, H., Wang, L., Lu, J., Jiang, F., Lu, A., and Zhang, G. (2017). Chemical modifications of nucleic acid aptamers for therapeutic purposes. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18081683"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Kumar, K.P., Hussain, B., and Y\u00fcce, M. (2020). Current Perspectives on Aptamers as Diagnostic Tools and Therapeutic Agents. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12070646"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1002\/cncr.26730","article-title":"An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancer","volume":"118","author":"Morrow","year":"2012","journal-title":"Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1039\/b411910j","article-title":"Deoxyribozymes: DNA catalysts for bioorganic chemistry","volume":"2","author":"Silverman","year":"2004","journal-title":"Org. Biomol. Chem."},{"key":"ref_84","first-page":"1","article-title":"Recent advances of DNAzyme-based nanotherapeutic platform in cancer gene therapy","volume":"123","author":"Huo","year":"2020","journal-title":"Biophys. Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1158\/0008-5472.CAN-18-2474","article-title":"Deoxyribozymes as Catalytic Nanotherapeutic Agents","volume":"79","author":"Khachigian","year":"2019","journal-title":"Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Zhang, J. (2018). RNA-Cleaving DNAzymes: Old Catalysts with New Tricks for Intracellular and In Vivo Applications. Catalysts, 8.","DOI":"10.3390\/catal8110550"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5982","DOI":"10.1093\/nar\/gkg791","article-title":"RNA cleaving \u201c10-23\u201d DNAzymes with enhanced stability and activity","volume":"31","author":"Schubert","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.7150\/thno.17736","article-title":"Theranostic DNAzymes","volume":"7","author":"Zhou","year":"2017","journal-title":"Theranostics"},{"key":"ref_89","unstructured":"Thesaurus, N.C.I. (2021, January 22). C-myb Antisense Oligonucleotide G4460 (Code C1541), Available online: https:\/\/ncithesaurus.nci.nih.gov\/ncitbrowser\/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1541."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1038\/sj.onc.1202839","article-title":"The myb gene family in cell growth, differentiation and apoptosis","volume":"18","author":"Oh","year":"1999","journal-title":"Oncogene"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/07357907.2018.1550090","article-title":"c-MYB and DMTF1 in Cancer","volume":"37","author":"Fry","year":"2019","journal-title":"Cancer Investig."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1073\/pnas.86.9.3379","article-title":"An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines","volume":"86","author":"Anfossi","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1093\/nar\/26.23.5425","article-title":"Highly efficient cellular uptake of c-myb antisense oligonucleotides through specifically designed polymeric nanospheres","volume":"26","author":"Tondelli","year":"1998","journal-title":"Nucleic Acids Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood.V99.4.1150","article-title":"Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: A pilot study","volume":"99","author":"Luger","year":"2002","journal-title":"Blood"},{"key":"ref_95","first-page":"321","article-title":"BCL-2 antisense oligonucleotide-Genta, G 3139, GC 3139, oblimersen sodium","volume":"8","author":"Oblimersen","year":"2007","journal-title":"Drugs R."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/sj.cdd.4400781","article-title":"The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability","volume":"7","author":"Harris","year":"2000","journal-title":"Cell Death Differ."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1098\/rsob.180002","article-title":"Targeting BCL-2 regulated apoptosis in cancer","volume":"8","author":"Campbell","year":"2018","journal-title":"Open Biol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s10495-008-0300-z","article-title":"Bcl2 family proteins in carcinogenesis and the treatment of cancer","volume":"14","author":"Frenzel","year":"2009","journal-title":"Apoptosis"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.2006.07.1191","article-title":"Randomized Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Sodium (Bcl-2 antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"25","author":"Moore","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00280-013-2361-0","article-title":"A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors","volume":"73","author":"Tolcher","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1200\/jco.2014.32.15_suppl.2586","article-title":"Pharmacokinetics of the BCL2-targeted DNA interference (DNAi) nanoparticle PNT2258 in patients with recurrent or refractory non-Hodgkin lymphoma","volume":"32","author":"Harb","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/leu.2010.322","article-title":"The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia","volume":"25","author":"Worm","year":"2011","journal-title":"Leukemia"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/bloodadvances.2019000937","article-title":"Venetoclax for AML: Changing the treatment paradigm","volume":"3","author":"Pollyea","year":"2019","journal-title":"Blood Adv."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"D\u2019Aguanno, S., and Del Bufalo, D. (2020). Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer. Cells, 9.","DOI":"10.3390\/cells9051287"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000080279","article-title":"Protein kinase C alpha expression in breast and ovarian cancer","volume":"67","author":"Lahn","year":"2004","journal-title":"Oncology"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Kazanietz, M.G. (2010). Protein Kinase C in Cancer Signaling and Therapy, Springer Science & Business Media.","DOI":"10.1007\/978-1-60761-543-9"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Pham, T.N.D., Perez, W.B.E., Zhao, H., Mortazavi, F., and Tonetti, D.A. (2017). Protein kinase C \u03b1 enhances migration of breast cancer cells through FOXC2-mediated repression of p120-catenin. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3827-y"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1053\/sonc.2003.37273","article-title":"Antisense therapy directed to protein kinase C-alpha (Affinitak, LY900003\/ISIS 3521): Potential role in breast cancer","volume":"30","author":"Roychowdhury","year":"2003","journal-title":"Semin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1158\/1078-0432.CCR-04-0779","article-title":"A phase I\/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer","volume":"10","author":"Ritch","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2005.04.3299","article-title":"Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer","volume":"24","author":"Douillard","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_111","first-page":"623","article-title":"Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: Initial report","volume":"22","author":"Lynch","year":"2003","journal-title":"Am. Soc. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1080\/21645515.2017.1327107","article-title":"Transforming growth factor-\u03b2: A therapeutic target for cancer","volume":"13","author":"Haque","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/j.1349-7006.2011.01917.x","article-title":"Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer","volume":"102","author":"Schlingensiepen","year":"2011","journal-title":"Cancer Sci."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.cytogfr.2005.09.002","article-title":"Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009","volume":"17","author":"Schlingensiepen","year":"2006","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_115","first-page":"445","article-title":"Trabedersen, a TGFbeta2-specific antisense oligonucleotide for the treatment of malignant gliomas and other tumors overexpressing TGFbeta2","volume":"12","year":"2009","journal-title":"Drugs"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1089\/oli.2006.0053","article-title":"Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: From preclinical to phase I\/II studies","volume":"17","author":"Hau","year":"2007","journal-title":"Oligonucleotides"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1586\/era.09.138","article-title":"Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotides","volume":"9","author":"Hau","year":"2009","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/neuonc\/noq142","article-title":"Targeted therapy for high-grade glioma with the TGF-\u03b22 inhibitor trabedersen: Results of a randomized and controlled phase IIb study","volume":"13","author":"Bogdahn","year":"2011","journal-title":"Neuro. Oncol."},{"key":"ref_119","unstructured":"(2021, March 23). The US Food and Drug Administration Trabedersen Orphan Drug Designations and Approvals, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=286709."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s10522-006-9052-8","article-title":"Clusterin\/Apolipoprotein J up-regulation after zinc exposure, replicative senescence or differentiation of human haematopoietic cells","volume":"7","author":"Trougakos","year":"2006","journal-title":"Biogerontology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.2147\/CMAR.S196273","article-title":"The role of Clusterin in cancer metastasis","volume":"11","author":"Peng","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1179\/1973947812Y.0000000049","article-title":"Clusterin confers resistance to TNF-alpha-induced apoptosis in breast cancer cells through NF-kappaB activation and Bcl-2 overexpression","volume":"24","author":"Wang","year":"2012","journal-title":"J. Chemother."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/S1470-2045(17)30605-8","article-title":"Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): A randomised, open-label, international, phase 3 trial","volume":"18","author":"Beer","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Saad, F., and Eisenberger, M.A. (2014). Management of Castration Resistant Prostate Cancer, Springer.","DOI":"10.1007\/978-1-4939-1176-9"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1470-2045(17)30168-7","article-title":"Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): A phase 3, multicentre, open-label, randomised trial","volume":"18","author":"Chi","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Abbas, R., and Larisch, S. (2020). Targeting XIAP for Promoting Cancer Cell Death-The Story of ARTS and SMAC. Cells, 9.","DOI":"10.3390\/cells9030663"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/COC.0000000000000099","article-title":"Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)","volume":"39","author":"Lee","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"421821","DOI":"10.1155\/2013\/421821","article-title":"Role of STAT3 in cancer metastasis and translational advances","volume":"2013","author":"Kamran","year":"2013","journal-title":"Biomed Res. Int."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Pham, T.-H., Park, H.-M., Kim, J., Hong, J.T., and Yoon, D.-Y. (2020). STAT3 and p53: Dual Target for Cancer Therapy. Biomedicines, 8.","DOI":"10.3390\/biomedicines8120637"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10928-019-09619-6","article-title":"Population pharmacokinetic analysis of danvatirsen supporting flat dosing switch","volume":"46","author":"Xu","year":"2019","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/nat.2013.0422","article-title":"Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys","volume":"23","author":"Burel","year":"2013","journal-title":"Nucleic Acid Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s40425-018-0436-5","article-title":"STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: Results of a phase 1b trial","volume":"6","author":"Reilley","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Choi, S.-K., Kam, H., Kim, K.-Y., Park, S.I., and Lee, Y.-S. (2019). Targeting Heat Shock Protein 27 in Cancer: A Druggable Target for Cancer Treatment?. Cancers, 11.","DOI":"10.20944\/preprints201907.0081.v1"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Calderwood, S.K., Sherman, M.Y., and Ciocca, D.R. (2007). Heat Shock Proteins in Cancer, Springer Science & Business Media.","DOI":"10.1007\/978-1-4020-6401-2"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1158\/1535-7163.MCT-14-0866","article-title":"Hsp27 Inhibition with OGX-427 Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy","volume":"14","author":"Kumano","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e1409","DOI":"10.1634\/theoncologist.2018-0518","article-title":"A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial","volume":"24","author":"Spigel","year":"2019","journal-title":"Oncologist"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s10637-017-0553-x","article-title":"A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer","volume":"36","author":"Yu","year":"2018","journal-title":"Investig. New Drugs"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1634\/theoncologist.2017-0066","article-title":"A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial","volume":"22","author":"Ko","year":"2017","journal-title":"Oncologist"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1073\/pnas.1813376116","article-title":"Mesyl phosphoramidate antisense oligonucleotides as an alternative to phosphorothioates with improved biochemical and biological properties","volume":"116","author":"Miroshnichenko","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3109\/10428194.2011.608451","article-title":"Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia","volume":"53","author":"Zent","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/annonc\/mdr030","article-title":"A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer","volume":"23","author":"Manegold","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1200\/JCO.2010.32.8971","article-title":"Randomized phase III trial of paclitaxel\/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer","volume":"29","author":"Hirsh","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1002\/cncr.24473","article-title":"Randomized phase 2\/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma","volume":"115","author":"Weber","year":"2009","journal-title":"Cancer"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1007\/s10637-014-0117-2","article-title":"Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-na\u00efve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R\/M SCCHN)","volume":"32","author":"Ruzsa","year":"2014","journal-title":"Investig. New Drugs"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2004-06-2156","article-title":"Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: Increased interferon-alpha\/beta-inducible gene expression, without significant toxicity","volume":"105","author":"Friedberg","year":"2005","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1158\/2159-8290.CD-18-0280","article-title":"SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study","volume":"8","author":"Ribas","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_147","first-page":"114","article-title":"How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market","volume":"30","author":"Bonneau","year":"2019","journal-title":"Ejifcc"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"7564","DOI":"10.1200\/JCO.2017.35.15_suppl.7564","article-title":"Phase 1 trial evaluating MRG-106, a synthetic inhibitor of microRNA-155, in patients with cutaneous t-cell lymphoma (CTCL)","volume":"35","author":"Foss","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/annonc\/mdt412","article-title":"Restoring expression of miR-16: A novel approach to therapy for malignant pleural mesothelioma","volume":"24","author":"Reid","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: A first-in-man, phase 1, open-label, dose-escalation study","volume":"18","author":"Pavlakis","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_151","first-page":"4672","article-title":"A phase II study of siG12D-LODER in combination with chemotherapy in patients with locally advanced pancreatic cancer (PROTACT)","volume":"38","author":"Varghese","year":"2020","journal-title":"J. Clin. Orthod."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"24560","DOI":"10.18632\/oncotarget.4183","article-title":"RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients","volume":"6","author":"Golan","year":"2015","journal-title":"Oncotarget"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-12-0429","article-title":"First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement","volume":"3","author":"Tabernero","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"11006","DOI":"10.1200\/jco.2015.33.15_suppl.11006","article-title":"Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors","volume":"23","author":"Tolcher","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1172\/JCI67544","article-title":"Melanoma immunotherapy using mature DCs expressing the constitutive proteasome","volume":"123","author":"Dannull","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s10637-013-0045-6","article-title":"A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma","volume":"32","author":"Rosenberg","year":"2014","journal-title":"Investig. New Drugs"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.3324\/haematol.2018.205930","article-title":"Olaptesed pegol (NOX-A12) with bendamustine and rituximab: A phase IIa study in patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"104","author":"Steurer","year":"2019","journal-title":"Haematologica"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood-2013-03-493924","article-title":"The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization","volume":"123","author":"Hoellenriegel","year":"2014","journal-title":"Blood"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Liao, W.-H., Yang, L.-F., Liu, X.-Y., Zhou, G.-F., Jiang, W.-Z., Hou, B.-L., Sun, L.-Q., Cao, Y., and Wang, X.-Y. (2014). DCE-MRI assessment of the effect of Epstein-Barr virus-encoded latent membrane protein-1 targeted DNAzyme on tumor vasculature in patients with nasopharyngeal carcinomas. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-835"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(12)62166-7","article-title":"Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: A phase 1 first-in-human trial (DISCOVER)","volume":"381","author":"Cho","year":"2013","journal-title":"Lancet"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13048-019-0573-6","article-title":"The Jun N-terminal kinases signaling pathway plays a \u201cseesaw\u201d role in ovarian carcinoma: A molecular aspect","volume":"12","author":"Dou","year":"2019","journal-title":"J. Ovarian Res."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1517\/14712598.2015.1025048","article-title":"DNA enzymes as potential therapeutics: Towards clinical application of 10-23 DNAzymes","volume":"15","author":"Fokina","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Willett","year":"2012","journal-title":"Nature"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc.2017.36","article-title":"Drugging the \u201cundruggable\u201d cancer targets","volume":"17","author":"Dang","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s13311-018-00702-3","article-title":"Oligonucleotide Therapeutics as a New Class of Drugs for Malignant Brain Tumors: Targeting mRNAs, Regulatory RNAs, Mutations, Combinations, and Beyond","volume":"16","author":"Krichevsky","year":"2019","journal-title":"Neurotherapeutics"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1182\/blood.V99.9.3461","article-title":"Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK\/MAPK pathways in acute myelogenous leukemia","volume":"99","author":"Milella","year":"2002","journal-title":"Blood"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/sj.onc.1206038","article-title":"Tumor regression by combination antisense therapy against Plk1 and Bcl-2","volume":"22","author":"Elez","year":"2003","journal-title":"Oncogene"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.4155\/fmc.15.144","article-title":"Oligonucleotide therapeutics: Chemistry, delivery and clinical progress","volume":"7","author":"Sharma","year":"2015","journal-title":"Future Med. Chem."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1038\/mtna.2015.23","article-title":"siRNA Versus miRNA as Therapeutics for Gene Silencing","volume":"4","author":"Lam","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_170","unstructured":"(2021, March 23). The US FDA Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-trial-endpoints-approval-cancer-drugs-and-biologics."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"5057s","DOI":"10.1158\/1078-0432.CCR-05-9012","article-title":"Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer","volume":"11","author":"Gandara","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1089\/nat.2018.0753","article-title":"Integrated Assessment of the Clinical Performance of GalNAc-Conjugated 2\u2032-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience","volume":"29","author":"Crooke","year":"2019","journal-title":"Nucleic Acid Ther."},{"key":"ref_173","unstructured":"Richard, M.J., and John, H.C. (2012). Designing Multi-Target Drugs, Royal Society of Chemistry."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3389\/fphar.2015.00209","article-title":"Developing multi-target therapeutics to fine-tune the evolutionary dynamics of the cancer ecosystem","volume":"6","author":"Xie","year":"2015","journal-title":"Front. Pharmacol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40487-017-0047-1","article-title":"DNA Mutations May Not Be the Cause of Cancer","volume":"5","author":"Adjiri","year":"2017","journal-title":"Oncol. Ther."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.addr.2018.07.011","article-title":"Harnessing albumin as a carrier for cancer therapies","volume":"130","author":"Hoogenboezem","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1093\/nar\/28.14.2717","article-title":"Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation","volume":"28","author":"Bijsterbosch","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"34501","DOI":"10.1039\/D0RA04978F","article-title":"In vivo and in vitro studies of antisense oligonucleotides\u2013a review","volume":"10","author":"Kilanowska","year":"2020","journal-title":"RSC Adv."},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Sparreboom, A., and Loos, W.J. (2004). Protein binding of anticancer drugs. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics, Springer.","DOI":"10.1007\/978-1-59259-734-5_12"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/jmr.2447","article-title":"Drug-drug plasma protein binding interactions of ivacaftor","volume":"28","author":"Schneider","year":"2015","journal-title":"J. Mol. Recognit."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"915375","DOI":"10.1155\/2012\/915375","article-title":"Combination drug delivery approaches in metastatic breast cancer","volume":"2012","author":"Lee","year":"2012","journal-title":"J. Drug Deliv."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/7\/3295\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:40:07Z","timestamp":1760161207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/7\/3295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,24]]},"references-count":181,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["ijms22073295"],"URL":"https:\/\/doi.org\/10.3390\/ijms22073295","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,24]]}}}